Conference News
From the Journals

AACR 2024: Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.

Share

Patients with metastatic, heavily pretreated KRAS G12C–mutated colorectal cancer showed promising survival outcomes when treated with the combination of the KRAS G12C inhibitor adagrasib and the anti-EGFR antibody cetuximab. The phase I/II KRYSTAL-1 trial revealed that the objective response rate was 34%, the disease control rate was 85.1%, and the responses lasted a median of 5.8 months. The adagrasib plus cetuximab combination therapy is currently under Priority Review by the U.S. Food and Drug Administration and also being evaluated in the phase III KRYSTAL-10 trial (ClinicalTrials.gov identifier NCT04793958).

Original Source(s)

AACR 2024: Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.

  • by Conexiant News Staff

  • May 2, 2024

  • 2 min

Related Content

Income, BMI Linked to Colon Capsule Completion

Danish screening data identify clinical and socioeconomic factors that significantly influence whether colon capsule exams are completed.

Biomarkers Expand Precision in CRC

Emerging biomarkers guide colorectal cancer diagnosis, stratification, and treatment selection

New NCI Grant to Foster Development of Novel Therapy in Metastatic Colorectal Cancer

The Case Western Reserve University School of Medicine received a 5-year $1.84 million grant to investigate the role of the LRG1 protein in colorectal cancer growth and develop a novel treatment option for patients with metastatic colorectal cancer.